Longitudinal assessment of disease activity and muscle strength in juvenile dermatomyositis: a multicentre registry study
Authors' conclusion
DAS20 scores improved gradually during follow up, MMT8 improved significantly during the first 6 months and CMAS, CHAQ-DI and parents VAS scores had no significant improvement with persistent functional impairment over 2-years.
Study context
- Population
- New-onset juvenile dermatomyositis (JDM) patients enrolled in a registry at 18 hospitals, 2015–201861 (64%) females
- Participants
- 96 patients
- Outcome
- Disease activity (DAS20, skin and musculoskeletal subscales), muscle strength (Manual Muscle Test (MMT8), CMAS) and function (CHAQ-DI, VAS wellbeing)
- Follow-up
- Baseline, 6, 12, 18 and 24 months
Methodological details18 hospitals, repeated measures (Poisson model, Wald post-test)
- 18 hospitals
- Repeated measures (Poisson model, Wald post-test)
Main finding
As reported in the abstract
Measured values over follow-up (baseline, then 6-month intervals) · diagnosis to 24 months
- Disease Activity Score (DAS20) (0-20), mean ±SD at diagnosis and 6-month intervals
- 7.8±5, 6.3 ±4.8, 5±4, 4.9 ±5 and 0.5 ±2.3; significant difference from baseline (p<0.01)
- Skin DAS subscale, mean ±SD
- 2.8±3.3, 1.8±2.9, 1,1±2.2, 0.6±1.8, 0.4±1.5
- MMT (0-80), mean ±SD
- 62.6±20.4, 70.2±13.5, 73.3±11, 75.7±7.9 and 74.8±7.8; significant difference from baseline up to 6 months (p=0.016)
- Childhood Myositis Assessment Scale (CMAS) (0-53), mean ±SD
- 29.5±11.4, 33.1±8.3, 34.2±5.8, 34±6 and 33.3±5.4
- CHAQ-DI (0-3), mean ±SD
- 1±0.9, 0.6±0.7, 0.8±0.8, 1±0.8 and 1±0.3
- Parents Visual Analog Scale (VAS), mean ±SD
- 4.1±2.5, 2±2.1; 1.3±2.8, 4.1±3.1, 1.7±2.2
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Onset calcinosis · diagnosis | JDM 13% |
Original publication
Longitudinal assessment of disease activity and muscle strength in juvenile dermatomyositis: a multicentre registry study. Clin Exp Rheumatol. Published 9 March 2024. doi:10. 55563/ clinexprheumatol/ yrb7m2
Composed by AI from the published abstract and checked against it. How Briefs are made →